Learning From Trials on Radiation Dose in Non-Small Cell Lung Cancer

Journal Article · Tue Nov 15 00:00:00 EST 2016 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2016.08.035· OSTI ID:22645694

Bradley, Jeffrey ^[1]; Hu, Chen ^[2]

---

1. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri (United States)
2. Division of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland (United States)

In this issue of the International Journal of Radiation Oncology • Biology • Physics, Taylor et al present a meta-analysis of published data supporting 2 findings: (1) radiation dose escalation seems to benefit patients who receive radiation alone for non-small cell lung cancer; and (2) radiation dose escalation has a detrimental effect on overall survival in the setting of concurrent chemotherapy. The latter finding is supported by data but has perplexed the oncology community. Perhaps these findings are not perplexing at all. Perhaps it is simply another lesson in the major principle in radiation oncology, to minimize radiation dose to normal tissues.

• OSTI ID: 22645694
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 96, Issue 4; Other Information: Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CHEMOTHERAPY
LUNGS
NEOPLASMS
RADIATION DOSES
RADIOTHERAPY